electroCore Inc.

NASDAQ: ECOR · Real-Time Price · USD
5.21
0.07 (1.36%)
At close: Aug 14, 2025, 3:59 PM
5.24
0.48%
Pre-market: Aug 15, 2025, 08:46 AM EDT

Company Description

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies.

The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years.

The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

electroCore Inc.
electroCore Inc. logo
Country United States
IPO Date Jun 22, 2018
Industry Medical - Devices
Sector Healthcare
Employees 73
CEO Daniel S. Goldberger

Contact Details

Address:
200 Forge Way
Rockaway, New Jersey
United States
Website https://www.electrocore.com

Stock Details

Ticker Symbol ECOR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001560258
CUSIP Number 28531P103
ISIN Number US28531P2020
Employer ID 20-3454976
SIC Code 3845

Key Executives

Name Position
Daniel S. Goldberger Chief Executive Officer & Director
Joshua S. Lev Chief Financial Officer
Brian M. Posner CPA, MBA. Consultant
Carrie Kochek Senior Director of Human Resources
Donald Melnikoff Senior Vice President of Engineering, Regulatory & Compliance
Dr. Peter S. Staats M.B.A., M.D. Chief Medical Officer
Dr. Thomas J. Errico M.D. Founder & Independent Director
Manuel A. Marques Senior Vice President of Operations
Michael Mansfield Vice President of Marketing
Mitch Deshon Vice President of Global Sales & Business Development

Latest SEC Filings

Date Type Title
Aug 13, 2025 4 Filing
Aug 12, 2025 4 Filing
Aug 06, 2025 10-Q Quarterly Report
Aug 06, 2025 8-K Current Report
Aug 05, 2025 4 Filing
Aug 05, 2025 3 Filing
Jul 18, 2025 S-3/A [Amend] Filing
Jul 17, 2025 DEF 14A Filing
Jul 16, 2025 8-K/A [Amend] Current Report
Jul 09, 2025 SCHEDULE 13G/A [Amend] Filing